All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
During the International Academy for Clinical Hematology (IACH) 2023 Congress, the MPN Hub spoke with Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked, Can ruxolitinib replace hydroxyurea as a frontline therapy for polycythemia vera?
Harrison begins by reflecting on current frontline treatment options for patients with polycythemia vera and mentions the introduction of ruxolitinib as a second-line treatment choice. She then discusses whether treatment with a drug is always an appropriate frontline option, outlining clinical scenarios when this should be strongly considered. Harrison continues by evaluating the choice of ruxolitinib or hydroxyurea, specifically in high-risk patients. Finally, she highlights important points from the recent phase II MAJIC-PV study (ISRCTN61925716).
Can ruxolitinib replace hydroxyurea as a frontline therapy for PV?
MAJIC-PV trial update: Clinical benefit of ruxolitinib for the treatment of PV
We summarize recent findings from the MAJIC-PV trial, which demonstrate clinical benefit of ruxolitinib treatment compared with best available therapy for patients with...
JAK inhibition in MPN: Updates from phase I/II trials at ASH 2022
Several exciting updates on developments in JAK inhibition for the treatment of MPN were presented at the 64th ASH Annual Meeting and Exposition. Here, we summarize key findings from...
Subscribe to get the best content related to MPN delivered to your inbox